Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BCEL Dec 2021 7.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
At close: 10:04AM EST
Advertisement
Full screen
Previous Close0.0500
Open0.0500
Bid0.0000
Ask0.0500
Strike7.50
Expire Date2021-12-17
Day's Range0.0500 - 0.0500
Contract RangeN/A
Volume1
Open Interest574
  • Simply Wall St.

    How Much Of Atreca, Inc. (NASDAQ:BCEL) Do Institutions Own?

    The big shareholder groups in Atreca, Inc. ( NASDAQ:BCEL ) have power over the company. Large companies usually have...

  • GlobeNewswire

    Atreca to Present at Upcoming Virtual Investor Conferences

    SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences: Cowen’s 5th Annual IO Next SummitMonday, November 15th, 2021Fireside chat time: 10:15 a.m. EST Stifel Nicolaus Healthcare Confere

  • GlobeNewswire

    Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

    SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments. "In the third quarter, we continued to advance our lead program, ATRC-101, following the re

Advertisement
Advertisement